Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIGHT 2: tepotinib plus osimertinib in MET-amplified EGFR-mutated NSCLC after osimertinib resistance
2024-512005-87-00Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, open-label trial of tepotinib and osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Objective response rate by independent review. Started Jul 2024; status: completed.
02
Drugs
tepotinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-512005-87-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512005-87-00.